Navigation Links
Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis
Date:3/11/2008

Lack of Flulike Side-Effects Drives Physician Prescribing of Copaxone over

an Interferon-Beta Therapy, According to a New Report from Decision

Resources

WALTHAM, Mass., March 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Teva Pharmaceutical's Copaxone has the greatest patient share among first- and second-line therapies, and falls short of Merck Serono/Pfizer's Rebif (by 0.2 percent) in third-line treatment. However, in all three lines of therapy, the interferon-beta drug class (Biogen Idec's Avonex, Rebif, and Berlex's Betaseron) outpaces the altered peptide ligand drug class (consisting only of Copaxone) in patient share. Competition between the two drug classes is fiercest in first-line therapy.

"The low volume of patient share attributed to Avonex or Rebif compared with Copaxone in first- and second-line treatment illustrates a significant delay on the part of physicians and/or patients to engage in an interferon- beta therapy within a year of a patient's initial diagnosis for multiple sclerosis," said Madhuri Borde, analyst at Decision Resources. "However, the magnitudes of Rebif's first- and second-line patient shares suggest that some physicians are treating the disease more aggressively than might be expected, as this high-dose, high-frequency agent reaches patient shares close to and surpassing Avonex in first- and second-line treatment, respectively."

According to the new report entitled Treatment Algorithms in Multiple Sclerosis, neurologists note that Copaxone's better short-term and long-term side-effect/safety profile, together with its lower rate of induction of neutralizing antibodies, are critical reasons for choosing Copaxone instead of Avonex, Rebif and Betaseron. Although Copaxone is administered daily, 23-28 percent of neurologists we surveyed indicate that a key reason to
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2014  CSSi ( www.CSSiEnroll.com ), the leader ... industry, is pleased to announce its participation in ... October.  President Chris Trizna will be ... Clinical Trials New England conference sponsored by Arena ... annual Site Solutions Summit sponsored by the Society ...
(Date:10/2/2014)... and BRIDGEWATER, N.J. , ... , a leader in synthetic biology, and ... drug manufacturer by volume in the U.S., today ... Collaboration (ECC) for a target active pharmaceutical ingredient ... goal of the collaboration is to develop a ...
(Date:10/1/2014)... What: , Cambridge Semantics, the leading provider ... technology, today announced its participation in the 2014 Big ... Data solutions provide semantic linkage and meaning to Big ... and manage diverse data. Ben Szekely, vice president and ... a “life sciences data lake” and an approach for ...
(Date:10/1/2014)... 1, 2014  Discovery Laboratories, Inc. (Nasdaq: DSCO) ... a Phase II Small Business Innovation Research Grant ... the National Institute of Allergy and Infectious Diseases ... to support the development of the Company,s aerosolized ... to mitigate acute and chronic/late-phase radiation-induced lung injury. ...
Breaking Biology Technology:Patient Recruitment Expert CSSi to be Featured at Upcoming Industry Events 2Patient Recruitment Expert CSSi to be Featured at Upcoming Industry Events 3Intrexon and Amneal Expand Relationship with Second Product Collaboration 2Intrexon and Amneal Expand Relationship with Second Product Collaboration 3Cambridge Semantics to Present ‘A Useful Approach to Big Data’ at 2014 Big Data Leaders Forum 2Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... , , , ... (Nasdaq: NBIX ) announced today that the Company will report ... Wednesday, July 29, 2009. Neurocrine will then host a ... a Company update Thursday morning, July 30, 2009 at 8:30 a.m. Eastern ...
... ASHLAND, Mass., July 23 MatTek Corp., today announced ... EpiDerm(TM) SIT non-animal alternative test method for determining the human ... , , This 20 minute ... (JoVE). Titled, "An In Vitro Skin Irritation Test (SIT) ...
... , , , ... to Severe Post-Operative Pain , , ... (Pink Sheets: QRXPY; ASX: QRX) announced today the initiation of a ... of MoxDuo(TM) IV (intravenous morphine and oxycodone) versus IV morphine alone ...
Cached Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results 2Video of EpiDerm Skin Irritation Test (SIT) Method Now Available 2QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study for MoxDuo(TM) IV Pain Therapy 2QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study for MoxDuo(TM) IV Pain Therapy 3
(Date:10/1/2014)... Case Western Reserve University researchers hope to take a ... for an aggressive form of breast cancer in leafy ... about administering the vaccine either by eating the salad ... Nicole Steinmetz, assistant professor of biomedical engineering at Case ... project. , The Susan G. Komen breast cancer organization ...
(Date:9/30/2014)... burning is published today in the first authoritative scientific ... tensions on both sides of the grouse moor management ... on the Ecohydrology of River basins) project has shown ... to support red grouse populations for gun sports, has ... physical properties, river water chemistry and river ecology. , ...
(Date:9/30/2014)... 2014--Sea monkeys have captured the popular attention of both ... life cycle -- sold as dehydrated eggs, these tiny ... more than a tank of salt water. , ... other zooplankton, brine shrimp vertically migrate in large groups ... the surface at night and retreating deeper during the ...
Breaking Biology News(10 mins):Scientists wield plant viruses against deadly human disease 2Scientists wield plant viruses against deadly human disease 3Grouse moor burning causes widespread environmental changes 2Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2
... SAN FRANCISCO -- The northernmost mummified forest ever found in ... global cooling. Researchers believe the trees -- buried by ... ago -- will help them predict how today,s Arctic will ... more mummified forests could emerge across North America as Arctic ...
... Two scientists at Scripps Institution of Oceanography at UC ... mysterious flashes of dazzling bioluminescent light produced by a ... of Scripps Oceanography (Wilson is now at the Australian ... a small marine snail typically found in tight clusters ...
... the little things that count, and that certainly holds ... enough to allow ions or molecules of a certain size ... nanochannels that mimic the capabilities of transmembrane proteins are highly ... been difficult to make individual artificial channels of this size ...
Cached Biology News:Ancient forest emerges mummified from the Arctic 2Ancient forest emerges mummified from the Arctic 3Scripps scientists see the light in bizarre bioluminescent snail 2Tiny channels carry big information 2Tiny channels carry big information 3
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Biology Products: